Literature DB >> 18924642

The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

Kimberly M Thompson1, Radboud J Duintjer Tebbens.   

Abstract

CONTEXT: Achieving successful eradication of a disease requires global cooperation to obtain a shared goal. Coordination of the endgame may seem an obvious requirement for success, but that does not ensure that cooperation will occur.
OBJECTIVE: To analytically explore the need for cooperation to maintain global polio eradication specifically related to creation of a global polio vaccine stockpile and coordination of oral poliovirus vaccine (OPV) cessation.
DESIGN: Using risk and decision analysis and game theoretical concepts, we modeled the importance of global cooperation in managing the risks associated with polioviruses for a time horizon of 20 years after successful global disruption of circulation of wild polioviruses.
RESULTS: Countries may wish to avoid the financial costs of vaccination and risks for vaccine-associated paralytic polio following eradication of wild polioviruses, which may lead them to reduce their use of OPV. However, reducing or stopping vaccination too soon and without coordination poses serious risks, including the possibility of reimportation of wild polioviruses and the possibility of vaccine-derived polioviruses. Analysis of the risks for potential outbreaks suggests the need for creation and maintenance of a global stockpile of vaccine for outbreak response. Game theoretical considerations show that coordination of OPV cessation optimizes expected costs and risks globally, despite the potential perceived incentives for countries to stop OPV earlier or later than other countries, or to continue OPV use indefinitely.
CONCLUSIONS: This article makes the strong case for global cooperation on risk management and suggests that even though individual countries may perceive their own risks as small, risks at the global level warrant cooperative action and coordination of OPV cessation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18924642      PMCID: PMC2562150     

Source DB:  PubMed          Journal:  Medscape J Med        ISSN: 1934-1997


  27 in total

1.  Policy decision options during the first 5 years following certification of polio eradication.

Authors:  Nalinee Sangrujee; Radboud J Duintjer Tebbens; Victor M Cáceres; Kimberly M Thompson
Journal:  MedGenMed       Date:  2003-12-18

Review 2.  Risk management in a polio-free world.

Authors:  R Bruce Aylward; Roland W Sutter; Steve L Cochi; Kimberly M Thompson; Hamid Jafari; David Heymann
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

3.  Evaluation of response scenarios to potential polio outbreaks using mathematical models.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

4.  The costs of future polio risk management policies.

Authors:  Radboud J Duintjer Tebbens; Nalinee Sangrujee; Kimberly M Thompson
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

Review 5.  Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management.

Authors:  Walter Dowdle; Harrie van der Avoort; Esther de Gourville; Francis Delpeyroux; Jagadish Desphande; Tapani Hovi; Javier Martin; Mark Pallansch; Olen Kew; Chris Wolff
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

6.  The polio eradication effort has been a great success--let's finish it and replace it with something even better.

Authors:  Tjeerd G Kimman; Hein Boot
Journal:  Lancet Infect Dis       Date:  2006-10       Impact factor: 25.071

7.  Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Victor M Cáceres; Hamid Jafari; Stephen L Cochi; Roland W Sutter; R Bruce Aylward; Kimberly M Thompson
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

Review 8.  Eradication versus control for poliomyelitis: an economic analysis.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

9.  Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.

Authors: 
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

Review 10.  Global health goals: lessons from the worldwide effort to eradicate poliomyelitis.

Authors:  R Bruce Aylward; Arnab Acharya; Sarah England; Mary Agocs; Jennifer Linkins
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

View more
  19 in total

1.  Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response.

Authors:  Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak
Journal:  Public Health Rep       Date:  2012 Jan-Feb       Impact factor: 2.792

2.  Economic considerations for the eradication endgame.

Authors:  Scott Barrett
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

3.  Modeling population immunity to support efforts to end the transmission of live polioviruses.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Stephen L Cochi
Journal:  Risk Anal       Date:  2012-09-17       Impact factor: 4.000

4.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

5.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

6.  Modeling poliovirus risks and the legacy of polio eradication.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

Review 7.  Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

8.  Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Radboud J Duintjer Tebbens
Journal:  Vaccine       Date:  2015-02-18       Impact factor: 3.641

Review 9.  Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Stephanie D Kovacs; Steven G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-07-06       Impact factor: 4.000

Review 10.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.